CoChat

Activin A–Induced Cachectic Wasting Is Attenuated by Systemic Delivery of Its Cognate Propeptide in Male Mice

The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.

Abstract

In cancer, elevated activin levels promote cachectic wasting of muscle, irrespective of tumor progression. In excess, activins A and B use the myostatin signaling pathway in muscle, triggering a decrease in protein synthesis and an increase in protein degradation, which ultimately leads to atrophy. Recently, we demonstrated that local delivery of engineered activin and myostatin propeptides (natural inhibitors of these growth factors) could induce profound muscle hypertrophy in healthy mice. Additionally, the expression of these propeptides effectively attenuated localized muscle wasting in models of dystrophy and cancer cachexia. In this study, we examined whether a systemically administered recombinant propeptide could reverse activin A–induced cachectic wasting in mice. Chinese hamster ovary cells stably expressing activin A were transplanted into the quadriceps of nude mice and caused an 85-fold increase in circulating activin A levels within 12 days. Elevated activin A induced a rapid reduction in body mass (−16%) and lean mass (−10%). In agreement with previous findings, we demonstrated that adeno-associated virus–mediated delivery of activin propeptide to the tibialis anterior muscle blocked activin-induced wasting. In addition, despite massively elevated levels of activin A in this model, systemic delivery of the propeptide significantly reduced activin-induced changes in lean and body mass. Specifically, recombinant propeptide reversed activin-induced wasting of skeletal muscle, heart, liver, and kidneys. This is the first study to demonstrate that systemic administration of recombinant propeptide therapy effectively attenuates tumor-derived activin A insult in multiple tissues.

Overview

Integrity signals

Registry

Crossref · 10.1210/en.2019-00257

Cites

34 of 34 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 34 references

Cited by

See all 24

Metadata

Authors
Walton, K. L., Chen, J. L., Arnold, Q., Kelly, E., La, M., Lu, L., Lovrecz, G., Hagg, A., Colgan, T. D., Qian, H., Gregorevic, P., & Harrison, C. A.
Affiliations
  • Hudson Institute of Medical Research (AU)
  • Baker Heart and Diabetes Institute (AU)
  • Commonwealth Scientific and Industrial Research Organisation (AU)
Corresponding author
  • Gregorevic, Paul
  • Harrison, Craig A
Venue
Endocrinology
Published
2019-07-19
Volume
160
Issue
10
Pages
2417-2426
ISSN
  • 0013-7227 (ISSN-L)
  • 1945-7170
OpenAlex
W2965577218
Cited by
23
References
34
Citations by year
2025: 2 · 2024: 2 · 2023: 5 · 2022: 5 · 2021: 5 · 2020: 4
FWCI
1.16
Type
journal article
Language
en
Open access
closed
Locations
  • Endocrinology (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • National Health and Medical Research Council (1078907, 1046782)
  • Cancer Council Victoria
  • Victorian Cancer Agency (ECSG14014)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Muscle Physiology and Disorders
  • Health Sciences › Medicine › Physiology (medical) › Nutrition and Health in Aging
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › TGF-β signaling in diseases
Keywords
activin A, cachexia, skeletal muscle atrophy, myostatin signaling, adeno-associated virus delivery, systemic administration, lean mass loss, muscle atrophy
MeSH terms
Animals, Cachexia, Cricetulus, Cricetinae, Kidney, Liver, Male, Myocardium, Organ Size, Peptides, CHO Cells, Muscle, Skeletal, Activins, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Activin A–Induced Cachectic Wasting Is Attenuated by Systemic Delivery of Its Cognate Propeptide in Male Mice. https://app.cochat.ai/papers/10.1210/en.2019-00257
The paper
Walton, K. L., Chen, J. L., Arnold, Q., Kelly, E., La, M., Lu, L., Lovrecz, G., Hagg, A., Colgan, T. D., Qian, H., Gregorevic, P., & Harrison, C. A. (2019). Activin A–Induced Cachectic Wasting Is Attenuated by Systemic Delivery of Its Cognate Propeptide in Male Mice. Endocrinology. https://doi.org/10.1210/en.2019-00257

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.